NASDAQ:AKBA - Akebia Therapeutics Stock Price, Forecast & News

Akebia Therapeutics trades on the NASDAQ under the ticker symbol "AKBA."

Akebia Therapeutics Inc (NASDAQ:AKBA) issued its quarterly earnings data on Tuesday, November, 12th. The biopharmaceutical company reported ($0.46) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.37) by $0.09. The biopharmaceutical company earned $91.98 million during the quarter, compared to analysts' expectations of $93.94 million. Akebia Therapeutics had a negative return on equity of 32.74% and a negative net margin of 75.39%. View Akebia Therapeutics' Earnings History.

Akebia Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, March 24th 2020. View Earnings Estimates for Akebia Therapeutics.

5 Wall Street analysts have issued 1-year price targets for Akebia Therapeutics' shares. Their forecasts range from $9.00 to $17.00. On average, they expect Akebia Therapeutics' share price to reach $13.80 in the next year. This suggests a possible upside of 117.3% from the stock's current price. View Analyst Price Targets for Akebia Therapeutics.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Akebia Therapeutics in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Akebia Therapeutics.

News headlines about AKBA stock have been trending negative this week, according to InfoTrie Sentiment. InfoTrie rates the sentiment of news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Akebia Therapeutics earned a daily sentiment score of -2.8 on InfoTrie's scale. They also gave media coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the next several days. View News Stories for Akebia Therapeutics.

Some companies that are related to Akebia Therapeutics include Deciphera Pharmaceuticals (DCPH), PTC Therapeutics (PTCT), Genmab A/S (GMAB), Uniqure (QURE), Emergent Biosolutions (EBS), Biohaven Pharmaceutical (BHVN), Agios Pharmaceuticals (AGIO), Eidos Therapeutics (EIDX), ArQule (ARQL), Zai Lab (ZLAB), Amicus Therapeutics (FOLD), Ultragenyx Pharmaceutical (RARE), Arena Pharmaceuticals (ARNA), Heron Therapeutics (HRTX) and Ra Pharmaceuticals (RARX).

Based on aggregate information from My MarketBeat watchlists, some companies that other Akebia Therapeutics investors own include Novavax (NVAX), Chesapeake Energy (CHK), Energy Transfer LP Unit (ET), FireEye (FEYE), TherapeuticsMD (TXMD), Gilead Sciences (GILD), Synergy Pharmaceuticals (SGYP), Bank of America (BAC), Netflix (NFLX) and Ford Motor (F).

Akebia Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional investors include State Street Corp (3.07%), Point72 Asset Management L.P. (1.49%), Rice Hall James & Associates LLC (1.25%), Man Group plc (0.31%), Massachusetts Financial Services Co. MA (0.29%) and Boston Partners (0.25%). Company insiders that own Akebia Therapeutics stock include Duane Nash, John P Butler, Steven C Gilman and Steven Keith Burke. View Institutional Ownership Trends for Akebia Therapeutics.

AKBA stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, Man Group plc, Millennium Management LLC, Squarepoint Ops LLC, Rice Hall James & Associates LLC and Metropolitan Life Insurance Co NY. View Insider Buying and Selling for Akebia Therapeutics.

AKBA stock was acquired by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Boston Partners, Massachusetts Financial Services Co. MA, California Public Employees Retirement System, Virginia Retirement Systems ET AL, Virtu Financial LLC, Rhumbline Advisers and SG Americas Securities LLC. Company insiders that have bought Akebia Therapeutics stock in the last two years include John P Butler, Steven C Gilman and Steven Keith Burke. View Insider Buying and Selling for Akebia Therapeutics.

Shares of AKBA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of AKBA stock can currently be purchased for approximately $6.35.

Akebia Therapeutics has a market capitalization of $755.27 million and generates $207.74 million in revenue each year. The biopharmaceutical company earns $-143,590,000.00 in net income (profit) each year or ($2.44) on an earnings per share basis. Akebia Therapeutics employs 324 workers across the globe.View Additional Information About Akebia Therapeutics.

The official website for Akebia Therapeutics is http://www.akebia.com/.

Akebia Therapeutics' mailing address is 245 FIRST STREET SUITE 1100, CAMBRIDGE MA, 02142. The biopharmaceutical company can be reached via phone at 617-871-2098 or via email at [email protected]